Kornimate/medical-research-clean huggingface dataset:
evaluating and monitoring physical fatigue while performing functional activities

Conditions: Stroke; Sarcopenia; Fatigue

Summary: fatigue is a critical health parameter in older adults and stroke patients and is associated with negative health outcomes. current assessment tools predominantly focus on walking related fatigue, neglecting other activities of daily living (adls). this study aims to fill this gap by developing a standardized, laboratory-based fatigue protocol that includes a broader range of adls, providing a more comprehensive fatigue assessment that's in line with the who vision of healthy ageing. the aim of this study is to evaluate a lab-based fatigue protocol and to unravel the relationship between physiological or movement data and perceived fatigue. participants will take part in three separate measurement moments, during which they will execute a performance task that induces fatigue. in addition, relevant sensors will be used to collect meaningful data.


Eligibility criteria:
stroke survivors: inclusion criteria: * \> 18 years old * ≥ 3 months ago stroke diagnosis * fac levels 3-5 exclusion criteria: * severe problems with speech or memory which prevents the participant to understand or follow instruction * co-morbidities that could influence the task execution and collected data older adults with sarcopenia: inclusion: * \> 65 years old * grip strength: \< 27 kg (man) or \< 16 kg (woman) * be mobile independently exclusion: * severe problems with speech or memory which prevents the participant to understand or follow instruction * co-morbidities that could influence the task execution and collected data healthy individuals: inclusion: * \> 18 years old * healthy physical and medical condition exclusion: * physical injury or disorder that doesn't allow good physical performance
sofosbuvir containing regimens for the treatment of chronic hcv gt2 infected patients

Conditions: Chronic Hepatitis C Infection

Summary: the purpose of this study is to assess the safety, tolerability, and efficacy of sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with hcv genotypes 2 infection.


Eligibility criteria:
inclusion criteria: 1. age equal to or greater than 18 years, with chronic genotype 2 hcv infection; 2. documented hcv treatment-naïve or treatment-experienced subjects who failed previous peg+rbv regimen; 3. hcv rna \> 10,000 iu/ml at screening; 4. screening laboratory values within defined thresholds 5. use of two effective contraception methods if female of childbearing potential or sexually active male exclusion criteria: 1. pregnant or nursing female or male with pregnant female partner; 2. hiv or chronic hepatitis b virus (hbv) infection; 3. hematologic or biochemical parameters at screening outside the protocol-specified requirements; 4. active or recent history (≤ 1 year) of drug or alcohol abuse; 5. hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers).
phase ii early behavioral intervention in bmt w/ sleep disturbance-assess qol+fatigue+cognitive f(x)

Conditions: Cognition Disorders; Fatigue; Sleep Disorders; Other Complications of Bone Marrow Transplant

Summary: this pilot clinical trial studies early brief behavioral intervention in treating sleep disturbance and improving quality of life in patients undergoing bone marrow transplant (bmt). a brief behavioral intervention may reduce symptoms of insomnia and fatigue and improve quality of life and cognitive function in patients undergoing bmt

primary objectives: i. to provide preliminary data on the feasibility and efficacy of brief behavioral treatment for insomnia (bbt-i) on insomnia in hematopoietic cell transplant (hct) recipients. secondary objectives: i. to provide preliminary data on the influence of bbt-i on cancer-related fatigue (crf) and cognitive status in bmt recipients. ii. to provide preliminary data on the influence of bbt-i on quality-of-life (qol) in bmt recipients. outline: patients complete the bbt-i, comprising the following modules: 1) "what to expect" in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) a review of the spielman model of insomnia; 3) a discussion (based on the spielman model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) an introduction to the concept and practice of stimulus control therapy; 5) an introduction to sleep scheduling specifically modified for cancer patients; 6) sleep compression; and 7) concomitant medications and substance use. after completion of study treatment, patients are followed up at 1 month.

Eligibility criteria:
patients proceeding to bmt within the stanford adult bmt program will be screened for eligibility inclusion criteria: * patient is scheduled to receive bone marrow transplantation. * patient has a diagnosis of non-hodgkin's lymphoma * patient is at least 21 years old * patient is able to understand written and spoken english * has preferred sleep phase between 9:00 pm and 3:00 am and a habitual rise time between 4:00 am and 11:00 am * patient receives a score of 8 or more on the insomnia severity index or takes sleep medications 3 times a week exclusion criteria: * has an unstable medical or psychiatric illness (axis i - current or within the last 5 years) * existing cognitive disability * is currently pregnant or nursing * has a history of substance abuse or meets criteria for current alcohol abuse or dependence * has a self-reported history of chronic pre-existing insomnia, sleep apnea or rsl syndrome

Keywords: quality of life
values-affirmation intervention targeting medication adherence in older adults with heart failure

Conditions: Heart Failure

Summary: heart failure (hf) represents a significant public health concern. medication non-adherence represents a modifiable contributor to costly hospital readmissions in older adults with hf. educational interventions improve, but do not eliminate, non-adherence. values affirmation interventions which invite individuals to reflect on core values may encourage better engagement in health behaviors by increasing the personal relevance of targeted behaviors. similar interventions have promoted weight loss, increased adherence and physical activity, and more frequent fruit and vegetable consumption in a variety of contexts and populations. this study seeks to test a recently developed values-affirmation intervention targeting medication adherence in older adults with hf enrolled in cardiac rehabilitation (cr). the purpose of this feasibility study is to test methodology to aid development of a subsequent randomized controlled pilot trial to examine preliminary efficacy.

the objective of this study is to examine the preliminary feasibility and acceptability of study procedures and the values-affirmation intervention in a single-arm trial. participants will be asked to complete a brief intervention with tailored education relevant to medication information, motivation, and behavioral skills. participants will complete a baseline assessment and a follow-up assessment at one month post-intervention. the investigators hypothesize that the developed study and intervention procedures will be feasible and acceptable to participants. the investigators will also examine changes in self-reported and electronically monitored medication adherence from the baseline assessment to follow-up.

Eligibility criteria:
inclusion criteria: * heart failure * enrolled in cardiac rehabilitation * read and understand english * at risk for medication non-adherence based on self-report screening or number of prescribed medications exclusion criteria: * current participation in another medication-monitoring clinical or research protocol * new york heart association class iv heart failure * diagnosis of alzheimer's, dementia, or severe cognitive impairment indicated on screening * current suicidality or psychosis * terminal illness with an expected lifespan of less than 6 months
safety of local dental anesthesia in patients with cardiac channelopathies

Conditions: Channelopathies; Brugada Syndrome; Long QT Syndrome; Ventricular, Tachycardia

Summary: patients with cardiac channelopathies needing restorative dental treatment will be included in two sessions of the study, using local dental anesthetic: lidocaine 2% with epinephrine and lidocaine 2% without vasoconstrictor. the safety of the use of two cartridges (3.6 ml) will be evaluated. the patients will be their own control and will be assessed by holter monitoring for 28 hours, blood pressure measurement and anxiety measuring.

patients of heart institute of the university of são paulo with inherited cardiac channelopathies will be included, considering the criteria for inclusion and non-inclusion, after reading and signing the informed consent. they will undergo dental restorative treatment in two sessions, in the morning period, with an interval of at least seven days (wash-out) between them, and the patients will be their own control. in the first session, after randomization, patients will receive lidocaine 2% without vasoconstrictor (lsa) or lidocaine 2% with 1: 100,000 epinephrine (lca) (cross-over), resulting in two conditions: with adrenaline and without adrenaline. the randomization of the anesthetic solution will be performed by the main researcher, being blind to the performer researcher and to the patient. the injected volume will be 3.6 ml (2 cartridges) of the anesthetic solution, using blocking technique of the inferior alveolar nerve. the patients will be monitored by holter for 28 hours starting one hour before the procedure, for registration and analysis of cardiac electrical activity during the two sessions. blood pressure will be monitored with digital sphygmomanometer and anxiety will be measured with facial image scale, both on three occasions: at the beginning of the baseline periods, before starting application of anesthesia and at the end of the proceedings. the results will be analyzed statistically.

Eligibility criteria:
inclusion criteria: * patients with any channelopathies below, kept on optimal drug therapy, with or without icd: brugada syndrome, long qt syndrome and catecholaminergic polymorphic ventricular tachycardia * dental caries or unsatisfactory restorations in the mandible, indicating restorative dental treatment exclusion criteria: * patients allergic to lidocaine * patients undergoing icd therapy for less than three months * patients with recurrent syncope in the last three months * patients with sustained arrhythmias documented for less than 3 months * have received epinephrine in the last 24 hours

Keywords: arrhythmias, cardiac channelopathies death, sudden genetic testing electrocardiography, ambulatory anesthesia, local dentistry
umbilical cord milking for neonates with hypoxic ischemic encephalopathy

Conditions: Hypoxic Ischemic Encephalopathy; Umbilical Cord Milking

Summary: the objective of this pilot study is to investigate the feasibility of performing umbilical cord milking in neonates who are depressed at birth.

hypoxic-ischemic encephalopathy (hie) is a brain injury in neonates due to inadequate blood flow and oxygen delivery to the neonatal brain. umbilical cord milking can potentially improve brain injury in neonates with hie. the objective of this study is to investigate the feasibility of performing umbilical cord milking in neonates who are depressed at birth. the investigators hypothesized that umbilical cord milking is feasible and safe in neonates who are depressed at birth. the investigators also hypothesized that umbilical cord milking will increase stem cells in neonatal blood circulation and improve short term outcomes in neonates with moderate and severe hie.

Eligibility criteria:
inclusion criteria: * term and near term neonates (35 weeks and more) * depressed at birth exclusion criteria: * congenital malformation of central nervous system * chromosomal abnormalities * major congenital malformations
effectiveness of triple therapy in copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: to assess the effectiveness of maintenance treatment of chronic obstructive pulmonary disease (copd) with the long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (laba-lama-ics) combination with a laba-lama combination on the risk of copd exacerbation and the safety on the incidence of community acquired pneumonia.


Eligibility criteria:
inclusion criteria: * new users of long-acting bronchodilators, long-acting beta2-agonist (laba) and long-acting muscarinic antagonists (lama) on the same date or of laba, lama and inhaled corticosteroids (ics), either as a fixed-dose combination (laba-ics) or free combination, on the same date between january 2002 and december 2016. * diagnosis of chronic obstructive pulmonary disease (copd) prior to first maintenance inhaler and age ≥ 55 years at first maintenance inhaler. exclusion criteria: * less than one year of medical history information prior to the date of combined treatment initiation (study cohort entry) * asthma diagnosis prior to study cohort entry
a phase i/ii study of vtx-801 in adult patients with wilson's disease

Conditions: Wilson's Disease

Summary: the objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of vtx-801, a gene therapy, administered intravenously (iv) to adult patients with wilson's disease prior to and following background wd therapy withdrawal.


Eligibility criteria:
main inclusion criteria: * male or female aged 18 and 65 years inclusive * confirmed diagnosis of wd * treated for wd according to international recommendations with no current evidence for inadequate treatment * stable wd for ≥ 1 year, defined as: (i) no significant change in neurologic examination and in status of mood disorder and (ii) stable laboratory parameters used to assess copper metabolism main exclusion criteria: * alt level ≥ 2 uln that is not readily explained by extrinsic factors * total bilirubin \> 1.5 x uln in the absence of proven gilbert's syndrome; in case of gilbert's syndrome, direct bilirubin \> uln * inr \> 1.2 * any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrollment visit * patient has moderate or severe renal impairment defined as egfr ckd-epi \< 60 ml/min/1.73 m2, or patient has nephritis or nephrotic syndrome * any history or current evidence of hiv-1, hiv-2, htlv 1, or htlv-2 infection * any history or current evidence of hepatitis b infection * any history of hepatitis c infection, unless previous viral rna assays in two samples, collected at least 6 months apart, are negative * positive quantiferon®-tb gold tuberculosis test result * any concomitant disorder/condition - including hepatic disorders - or treatment possibly interfering with the conduct or evaluation of the study * any history of diabetes * pregnancy or breastfeeding * body mass index ≥ 35 kg/m2 other protocol defined inclusion/ exclusion criteria may apply
trends and satisfaction in hypertensives using aktiia optical bp monitoring device (shine)

Conditions: Hypertension

Summary: the shine study aims to gather data on the evolution of participant's blood pressure and to correlate this with demographic, lifestyle and health factors in a hypertensive population as well as, to gather data on participants' perception of the device under test (aktiia 24/7).


Eligibility criteria:
inclusion criteria: 1. adult participants aged 22 to 85 years old 2. a participant whose last blood pressure reading was within the last 12 months and was either: 1. sbp ≥145 2. or ≥dbp 90 3. people who use either an ios or android smartphone 4. people who have 2 arms 5. able and willing to provide informed consent and to adhere to study procedures. exclusion criteria: 1. participants whose bp data submitted is \>180 mm hg systolic or \>120 mm hg diastolic . 2. participants with a self-reported known diagnosis of 1. atrial fibrillation 2. congestive heart failure 3. heart valve disease 4. pheochromocytoma 5. raynaud's disease 6. arm lymphedema 3. participants who take insulin 4. participants who are on hemodialysis 5. women who are self-reported to be pregnant 6. participants whose arms shake uncontrollably or are paralyzed (cannot move) 7. participants with upper arm circumference \ 42 cm 8. participants with wrist circumference \>23cm 9. participation in another interventional clinical study or use of investigational drugs in the last 30 days.
study to evaluate the safety and efficacy of usl261 in patients with increased bouts of seizure activity in the emu

Conditions: Epilepsy

Summary: this study is designed to evaluate the efficacy, safety, and tolerability of usl261 compared with that of intranasal (in) placebo for the treatment of intermittent bouts of increased seizure activity.


Eligibility criteria:
inclusion criteria: * subject has been admitted to the institution's emu for seizure characterization or pre-surgical evaluation, or such admission is planned within 28 days * subject body weight is ≥ 40 kg to ≤ 125 kg (inclusive) * subject has an established diagnosis of partial or generalized epilepsy exclusion criteria: * subject has history of status epilepticus in the 6 months prior to screening * subject has a progressive neurological disorder such as brain tumor, demyelinating disease, or degenerative central nervous system (cns) disease that is likely to progress in the next 12 months * subject has respiratory failure (or is at risk for respiratory failure) or other severe cardiorespiratory disease with new york heart association class iii or iv functional status, or requires supplemental oxygen * subject has acute narrow-angle glaucoma * subject is receiving chronic benzodiazepine treatment (defined as an average of ≥ 4 administrations per week) and cannot safely withdraw from such treatment within the washout period prior to treatment

Keywords: epilepsy seizure clusters acute repetitive seizures rescue treatment
radiofrquency ablation combined with cytokine-induced killer cells for colorectal cancer liver metastases

Conditions: Colorectal Cancer

Summary: the purpose of this study is to determine whether combining of radiofrequency ablation (rfa) and cytokine-induced killer cells (cik) transfusion can prolong survival of patients with colorectal cancer liver metastases (crclm).

the primary objective is to evaluate whether rfa followed by cik transfusion can prolong survival of patients with resectable crclm.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed adenocarcinoma * primary lesions (colorectal cancer) are resected * must have undergone prior complete resection of the primary tumor; liver metastases * must be resectable or accessible for radiofrequency ablation (five or less lung metastases measuring 5 cm or smaller). * serum bilirubin level of 2.0 mg/dl or less. * performance status of 0 or 1. * expected survival of 1 year or more. * informed consent from the patient. exclusion criteria: * with extrahepatic metastases * with other neoplastic disease that is measurable or being treated other than colorectal cancer.

Keywords: radiofrequency ablation cytokine-induced killer cells colorectal cancer iver metastases
the effect of a new emulsion in dry eye patients on tear layer aberrometry, contrast sensitivity, and reading ability

Conditions: Dry Eye Syndrome

Summary: the purpose of this study is to investigate how the addition of a new emulsion artificial tear to the tear layer of dry eye and normal patients affects aberrometry, contrast sensitivity, and reading ability over time. previous studies have indicated that daily use of artificial tears over a two week period decreases the short term affect of drop application on aberrometry and contrast sensitivity measurements. the present study will examine the effects of 4 weeks of artificial tear use to determine when the responses stabilize.

dry eye patients experience symptoms such as; irritation, dryness, a scratchy sensation, and blur. these symptoms are the result of an insufficient tear layer. blur can occur in dry eye patients because of an irregular tear film surface. artificial tears are applied to the eye to treat a variety of eye conditions. these conditions typically are associated with dry eyes and include tear film deficiency due to ocular or systemic disease, lid resurfacing problems, and contact lens wear. the artificial tears are used to alleviate the dry eye symptoms. dry eye is a frequently encountered ocular condition. recent studies estimate that 7.8% of women and 4.8% of men over the age of 50 suffer from dry eye. the administration of an artificial tear to the eye can disrupt the tear layer and this disruption could then result in a change in contrast sensitivity for a few moments. aberrometry is a technique that is able to monitor tear layer disruption and its results may correlate with contrast sensitivity changes. tear layer disruption results in a decrease in the modulation transfer function (mtf) for the eye. since the tear layer is the first refracting surface of the eye, its disruption can also result in a change in contrast sensitivity, visual acuity, and aberrometry. previous work has demonstrated that higher order aberrations increase 1.44 fold after the tear film breaks up in normal subjects. dry eye subjects demonstrate a significant increase in higher order aberrations (i.e., total s3+4+5, spherical-like s4, and coma-like s3+5) when compared to normal subjects. this has been interpreted to be the result of increased tear irregularities in the dry eye subjects. when an artificial tear (i.e., vismed) was applied to the tear layer of dry eye subjects, the optical aberrations decreased. this previous study only examined the short term affect (less than 10 minutes) of a single administration of an artificial tear. in this study, we propose to examine the short and long term effects of a new emulsion on contrast sensitivity, optical aberrations, and reading ability after administration into the tear layer of normal and dry eye subjects.

Eligibility criteria:
inclusion criteria: * mild, moderate, or severe symptoms of dry eye exclusion criteria: * uncontrolled systemic disease * contact lens wear * participation in another clinical trial * best corrected visual acuity poorer than 20/25

Keywords: functional vision contrast sensitivity aberrometry reading ability
retrospective examination of electroencephalography signals of individuals with different eating disorders

Conditions: Anorexia Nervosa; Bulimia Nervosa

Summary: the aim of this study was to investigate the difference between electroencephalography (eeg) data and current psychological status of individuals diagnosed with anorexia nervosa (an) and bulimia nervosa (bn).

the data used in this study were obtained from individuals aged 18 and younger with eating disorders who applied to üsküdar university np istanbul brain hospital. two different diagnostic groups, anorexia nervosa and bulimia nervosa, were included in the study. demographic information, secondary diagnosis status, beck depression inventory (bdi), beck anxiety inventory (bai), eating attitude test - 40 (eat-40) scores and eeg data were used to investigate the differences between eating disorders. comparison of neurological differences between individuals with an and bn was done retrospectively. this information, which will be obtained for an and bn, which are diseases in which severe deterioration in behavior and perception are seen, can give advice to experts in planning treatment and rehabilitation processes.

Eligibility criteria:
inclusion criteria: * being diagnosed with anorexia nervosa or bulimia nervosa to the dsm-v diagnostic criteria * 18 years and younger * having an eeg data exclusion criteria: * having an eeg data taken in a center other than np istanbul brain hospital * lack of "beck depression inventory", "beck anxiety inventory" and "eating attitude test-40" scale values in the patient file

Keywords: eating disorders electroencephalography depression